Raaj medisafe India Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling mandatory regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The submission, dated April 10, 2026, covers the quarter ended March 31, 2026.

Regulatory Compliance Certificate

The company submitted the confirmation certificate received from M/s. Ankit Consultancy Pvt. Ltd., which serves as the Registrar and Share Transfer Agent (RTA) for Raaj Medisafe India Limited. This certificate is mandated under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Certificate Confirmation Details

Ankit Consultancy Pvt. Ltd., dated April 2, 2026, confirmed several key compliance aspects for the quarter:

• Securities received from depository participants for dematerialization were properly confirmed to depositories
• All securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed
• Security certificates received for dematerialization were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners within the prescribed 15-day timeframe

Company Information

Raaj Medisafe India Limited, formerly known as Manoj Surgical Ind. Ltd., operates from its registered office at 75/2 and 3, Industrial Area, Maxi Road, Ujjain-456010. The company is incorporated under CIN L33112MP1985PLC003039.

The certificate submission represents routine quarterly compliance activity, ensuring adherence to securities market regulations and proper processing of dematerialization requests during the specified period.

Raaj Medisafe India Limited has successfully completed the allotment of 32,75,000 equity shares through preferential issue following the board meeting held on March 26, 2026. The pharmaceutical company had previously announced this board meeting on March 20, 2026, in compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Board Meeting Outcome

The board meeting was conducted at the company's registered office and concluded with the approval of the preferential share allotment. The meeting details and outcomes demonstrate the company's commitment to regulatory compliance and strategic capital raising.

Share Allotment Details

The company successfully allotted shares to 17 non-promoter investors, raising significant capital for business operations. The allotment was conducted on a preferential basis with cash consideration, and the new shares will rank pari-passu with existing equity shares.

Regulatory Compliance Framework

Raaj Medisafe India Limited received in-principle approval from BSE Limited on March 12, 2026, for the preferential issue. The company has committed to filing the listing approval application for the newly allotted shares in due course, maintaining full compliance with regulatory requirements.

The announcement was signed by Arpit Bangur, Managing Director with DIN 02600716, and communicated to the Bombay Stock Exchange Limited. The company's registered office is located at 75/2 and 3, Industrial Area, Maksi Road, Ujjain-456010, where the board meeting was conducted.

Strategic Capital Raising Initiative

The preferential allotment represents a significant capital raising initiative that will strengthen the company's financial position. The shares were issued under Chapter V of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, and applicable provisions of Companies Act 2013.

The company has ensured complete transparency by providing detailed disclosures as required under Regulation 30 of the Listing Regulations and SEBI Circular on Continuous Disclosure. The successful completion of this preferential issue demonstrates investor confidence in the pharmaceutical company's growth prospects and business strategy.